News

Article

Sartorius to Acquire Polyplus in $2.6 Billion Deal

Author(s):

Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.

Sartorius announced on March 31, 2023, that it had agreed to acquire Polyplus, a company specializing in developing materials for cell and gene therapies, for €2.4 billion (US$2.6 billion). Polyplus is a French developer and producer of transfection reagents, as well as various other DNA/RNA delivery reagents, ingredients critical in the production of viral vectors. According to a company press release, in addition to transfection reagents Polyplus has broadened its upstream portfolio for gene therapies through acquisitions in plasmid design, protein manufacturing, and plasmid manufacturing.

“The innovative solutions of Polyplus are highly complementary to our portfolio, in particular to our offering of cell culture media and critical components for the development and manufacture of advanced therapies, and there are also strong synergies with our portfolio of downstream solutions for the manufacture of gene therapeutics,” said René Fáber, member of the Executive Board, head of Bioprocess Solutions, Sartorius, in the release. “In the dynamically growing market for cell and gene therapies, viral vectors are needed to deliver the genes of interest into cells. The development pipeline of such therapies has been growing strongly and more and more are reaching major milestones. As a leading supplier of critical components to produce cell and gene therapies, Sartorius and Polyplus together will be excellently positioned to play a significant role in this dynamic field.”

“We would be excited to join forces with a world class bioprocess market leader as Sartorius,” said Mario Philips, CEO, Polyplus, in the release. “Our combined portfolios would create a unique ability to optimize the total process workflow to deliver unparalleled value for cell/gene and DNA/RNA therapy customers, in a strong effort to make these critical needed therapies more affordable.”

Sartorius signed an agreement to make the acquisition through its subgroup, Sartorius Stedim Biotech. The transaction is expected to close in the third quarter of 2023.

Source: Sartorius

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content